Past Events

View upcoming events

ESCRS
Safety and Efficacy of a Novel Integrin Inhibitor ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

Presented by Eric Donnenfeld, M.D.
September 16, 2019
Paris Expo Porte de Versailles, Paris, France

The Retina Society 2019 Annual Meeting
Safety and Efficacy of Risuteganib in Intermediate Non-exudative (Dry) Age-Related Macular Degeneration (AMD): Primary Results from a Phase 2 Study

Presented by David S. Boyer, M.D.
September 12, 2019
The Landmark London, London, UK

EURETINA
Safety and Efficacy of Risuteganib in Non Exudative Age-Related Macular Degeneration: Primary Results from a Phase 2 Study

Presented by Peter K. Kaiser, M.D.
September 8, 2019
Palais des Congrès, Paris, France

American Society of Retina Specialists (ASRS) Annual Meeting 2019
Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-related Macular Degeneration—First Time Results from a Phase 2 Study

Presented by Peter K. Kaiser, MD
July 27, 2019
Hyatt Regency Chicago

OIS@ASRS 2019
Addressing the Unmet Need of Ocular Diseases with a Novel Integrin-Regulating Portfolio

Presented by Vicken Karageozian, MD
July 25, 2019
The Ritz-Carlton Chicago

2019 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
A Pilot Study to Evaluate the Safety and Exploratory Efficacy of ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease. SPS-308: Ocular Surface

Presented by Eric D. Donnenfeld, MD
May 6, 2019
San Diego Convention Center

OIS@ASCRS 2019
Addressing the Unmet Need of Ocular Diseases with a Novel Anti-integrin Portfolio

Presented by Vicken Karageozian, MD
May 2, 2019
Hilton San Diego Bayfront

View 2018 Events